Skip to content

Magnesium Sulfate Combined With Intraarticular Cocktail Injection for Analgesia After Simultaneous Bilateral Total Knee Arthroplasty

Magnesium Sulfate Combined With Intraarticular Cocktail Injection for Analgesia After Simultaneous Bilateral Total Knee Arthroplasty

Status
Not yet recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06445829
Enrollment
80
Registered
2024-06-06
Start date
2024-06-30
Completion date
2026-04-30
Last updated
2024-06-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoarthritis, Knee

Keywords

intraarticular injection

Brief summary

Total knee arthroplasty is a safe procedure with excellent outcome. In recent years, simultaneous bilateral total knee arthroplasty has become more popular. In views of enhanced recovery after surgery, intraarticular cocktail injection for pain control has been developed. However, the safety accumulation dose for simultaneous bilateral knee injection is still an issue. Recently, adding magnesium sulfate to intraarticular cocktail injection in unilateral total knee arthroplasty has been proved effective for prolong pain control. We tempt to conduct a double blinded study to evaluate that whether adding magnesium sulfate intraarticular cocktail injection to one of the knees in simultaneous bilateral total knee arthroplasty patient could effectively decrease pain score with less analgesia dose or not.

Interventions

DRUGMagnesium sulfate

adding 300mg magnesium sulfate into cocktail injection

Sponsors

Chang Gung Memorial Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* bilateral knee advanced osteoarthritis or osteonecrosis who tend to receive simultaneous bilateral total knee arthroplasty

Exclusion criteria

* hypersensitivity to magnesium sulfate * hypermagnesemia * severe cardiac, hepatic or renal compromised

Design outcomes

Primary

MeasureTime frame
VAS scoreday 0, day 1, day 2, day 3, day 7
muscle powerday 0, day 1, day 2, day 3
Straight leg raised testday 0, day 1, day 2, day 3
active range of motionday 0, day 1, day 2, day 3

Secondary

MeasureTime frame
Magnesium level in bloodday 0, day 1
Calcium level in bloodday 0, day 1

Contacts

Primary ContactShih Hui Peng
b9502066@gmail.com+886975360757

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026